Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis

Modeling vitamin D insufficiency and moderate deficiency in adult mice via dietary cholecalciferol restriction

(2016) Sanjay M. Mallya et al.   ENDOCRINE RESEARCH

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

(2016) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis

(2015) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Severe hypercalcemia following denosumab treatment in a juvenile patient

(2015) Nokitaka Setsu et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys

(2015) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

(2015) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis

(2014) Kosuke Ebina et al.   Modern Rheumatology

Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in RA patients: response to Mokuda

(2014) K. Ebina et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients

(2014) K. Ebina et al.   OSTEOPOROSIS INTERNATIONAL

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) T. Sugimoto et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

RANKL subcellular trafficking and regulatory mechanisms in osteocytes

(2013) Masashi Honma et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

(2013) Chris Recknor et al.   OBSTETRICS AND GYNECOLOGY

Eldecalcitol and calcitriol stimulates ‘bone minimodeling,’ focal bone formation without prior bone resorption, in rat trabecular bone

(2012) Hitoshi Saito et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

The role of osteocalcin in human glucose metabolism: marker or mediator?

(2012) Sarah L. Booth et al.   Nature Reviews Endocrinology

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary

(2012) Hajime Orimo et al.   Archives of Osteoporosis

Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO study

(2011) A Chaitou et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Alfacalcidol treatment increases bone mass from anticatabolic and anabolic effects on cancellous and cortical bone in intact female rats

(2011) Xiao Qing Liu et al.   JOURNAL OF BONE AND MINERAL METABOLISM

PTH level but not 25 (OH) vitamin D level predicts bone loss rates in the elderly

(2011) A. Arabi et al.   OSTEOPOROSIS INTERNATIONAL

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

(2010) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Relative Influence of Calcium Intake and Vitamin D Status on Serum Parathyroid Hormone and Bone Turnover Biomarkers in a Double-Blind, Placebo-Controlled Parallel Group, Longitudinal Factorial Design

(2010) John Aloia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Potential of alfacalcidol for reducing increased risk of falls and fractures

(2009) J. D. Ringe et al.   RHEUMATOLOGY INTERNATIONAL

Alfacalcidol-Stimulated Focal Bone Formation on the Cancellous Surface and Increased Bone Formation on the Periosteal Surface of the Lumbar Vertebrae of Adult Female Rats

(2008) HaiYan Chen et al.   CALCIFIED TISSUE INTERNATIONAL

Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis

(2008) Florent Richy et al.   CALCIFIED TISSUE INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH